A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

NCT00401479 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome (IBS)

Interventions

DRUG: Placebo
DRUG: Solabegron (GW427353)

Sponsor

GlaxoSmithKline